tm
Seeing Is Believing
tm
Seeing Is Believing
Healthcare - Sector
CAPR is currently covered by 7 analysts with an average price target of $50.74. This is a potential upside of $22.39 (78.98%) from yesterday's end of day stock price of $28.35.
Capricor Therapeutics's activity chart (see below) currently has 36 price targets and 53 ratings on display. The stock rating distribution of CAPR is 100% BUY.
Analysts average stock forecasts to be materialized ratio is 66.56% with an average time for these price targets to be met of 359.29 days.
Highest price target for CAPR is $60, Lowest price target is $29, average price target is $44.67.
Most recent stock forecast was given by EDWARD TENTHOFF from PIPER SANDLER on 10-Dec-2025. First documented stock forecast 15-Sep-2017.
Currently out of the existing stock ratings of CAPR, 20 are a BUY (100%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 21-Oct-2024
$45
$16.49 (57.84%)
$43
2 months 15 days ago
(10-Dec-2025)
0/4 (0%)
$16.33 (56.96%)
Buy Since 17-May-2024
$54
$32.11 (146.69%)
$22
2 months 17 days ago
(08-Dec-2025)
4/5 (80%)
$25.44 (89.08%)
81
Buy Since 03-Feb-2020
$50
$21.49 (75.38%)
$25
2 months 21 days ago
(04-Dec-2025)
5/6 (83.33%)
$24.6 (96.85%)
749
Buy Since 15-Jul-2019
$60
$31.49 (110.45%)
$24
2 months 22 days ago
(03-Dec-2025)
9/13 (69.23%)
$30.04 (100.27%)
670
Buy Since 05-Jan-2024
$30
$1.49 (5.23%)
$30
8 months 1 days ago
(24-Jun-2025)
7/7 (100%)
$20.75 (224.32%)
216
What is CAPR (Capricor Therapeutics) average time for price targets to be met?
Which analyst has the current highest performing score on CAPR (Capricor Therapeutics) with a proven track record?
Which analyst has the current lower performing score on CAPR (Capricor Therapeutics) with a proven track record?
Which analyst has the most public recommendations on CAPR (Capricor Therapeutics)?
Which analyst is the currently most bullish on CAPR (Capricor Therapeutics)?
Which analyst is the currently most reserved on CAPR (Capricor Therapeutics)?
